Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.
Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Chianese-Bullock KA, Mauldin IS, Smith KT, Deacon DH, Varhegyi NE, Donnelly SB, Reed CM, Scott K, Galeassi NV, Grosh WW. Slingluff CL Jr, et al. Among authors: grosh ww. Cancer Immunol Immunother. 2016 Jan;65(1):25-36. doi: 10.1007/s00262-015-1770-9. Epub 2015 Nov 18. Cancer Immunol Immunother. 2016. PMID: 26581199 Free PMC article. Clinical Trial.
Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH. Slingluff CL Jr, et al. Among authors: grosh ww. J Clin Oncol. 2003 Nov 1;21(21):4016-26. doi: 10.1200/JCO.2003.10.005. J Clin Oncol. 2003. PMID: 14581425 Clinical Trial.
Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.
Slingluff CL Jr, Petroni GR, Yamshchikov GV, Hibbitts S, Grosh WW, Chianese-Bullock KA, Bissonette EA, Barnd DL, Deacon DH, Patterson JW, Parekh J, Neese PY, Woodson EM, Wiernasz CJ, Merrill P. Slingluff CL Jr, et al. Among authors: grosh ww. J Clin Oncol. 2004 Nov 15;22(22):4474-85. doi: 10.1200/JCO.2004.10.212. J Clin Oncol. 2004. PMID: 15542798 Clinical Trial.
MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, Petroni GR, Bissonette EA, Neese PY, Grosh WW, Merrill P, Fink R, Woodson EM, Wiernasz CJ, Patterson JW, Slingluff CL Jr. Chianese-Bullock KA, et al. Among authors: grosh ww. J Immunol. 2005 Mar 1;174(5):3080-6. doi: 10.4049/jimmunol.174.5.3080. J Immunol. 2005. PMID: 15728523
Immunity to melanoma antigens: from self-tolerance to immunotherapy.
Slingluff CL Jr, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M, Engelhard VH. Slingluff CL Jr, et al. Among authors: grosh ww. Adv Immunol. 2006;90:243-95. doi: 10.1016/S0065-2776(06)90007-8. Adv Immunol. 2006. PMID: 16730266 Review.
Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting.
Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK. Slingluff CL Jr, et al. Among authors: grosh ww. Clin Cancer Res. 2007 Nov 1;13(21):6386-95. doi: 10.1158/1078-0432.CCR-07-0486. Clin Cancer Res. 2007. PMID: 17975151 Clinical Trial.
Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
Slingluff CL Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, Chianese-Bullock KA, Neese PY, Deacon DH, Nail C, Merrill P, Fink R, Patterson JW, Rehm PK. Slingluff CL Jr, et al. Among authors: grosh ww. J Clin Oncol. 2008 Oct 20;26(30):4973-80. doi: 10.1200/JCO.2008.17.3161. Epub 2008 Sep 22. J Clin Oncol. 2008. PMID: 18809608 Free PMC article. Clinical Trial.
Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.
Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Ross MI, Haas NB, Grosh WW, Boisvert ME, Kirkwood JM, Chianese-Bullock KA. Slingluff CL Jr, et al. Among authors: grosh ww. Clin Cancer Res. 2009 Nov 15;15(22):7036-44. doi: 10.1158/1078-0432.CCR-09-1544. Epub 2009 Nov 10. Clin Cancer Res. 2009. PMID: 19903780 Free PMC article. Clinical Trial.
Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.
Slingluff CL, Petroni GR, Smolkin ME, Chianese-Bullock KA, Smith K, Murphy C, Galeassi N, Neese PY, Grosh WW, Nail CJ, Ross M, von Mehren M, Haas N, Boisvert ME, Kirkwood JM. Slingluff CL, et al. Among authors: grosh ww. J Immunother. 2010 Jul-Aug;33(6):630-8. doi: 10.1097/CJI.0b013e3181e311ac. J Immunother. 2010. PMID: 20551833 Free PMC article. Clinical Trial.
51 results